References
- American Cancer Society: Cancer Facts & Figures 20OED. Atlanta: American Cancer Society; 2017 Available from :URL: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
- National Cancer Center, Annual report of cancer statistics in Korea in 2015, 2017 Available from :URL: http://ncc.re.kr/cancerStatsView.ncc?bbsnum=438&searchKey=total&searchValue=&pageNum=1
- Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007 https://doi.org/10.1038/nature05945
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-550, 2014 https://doi.org/10.1038/nature13385
- Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, and Iafrate AJ. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009 https://doi.org/10.1200/JCO.2009.22.6993
- Stoica GE1, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277:35990-35998, 2002 https://doi.org/10.1074/jbc.M205749200
- Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385-2394, 2013 https://doi.org/10.1056/NEJMoa1214886
- Reynolds C, Masters ET, Black-Shinn J, Boyd M, Mardekian J, Espirito JL, Chioda M. Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. Journal of Clinical Medicine 7(6):129, 2018 https://doi.org/10.3390/jcm7060129
- Kang HJ, Park SJ, Park YM, Yoo HS, Kang IC. Inhibitory effects of HangAmDan-B1 (HAD-B1) on A549 lung cancer cell proliferation and tumor growth in a xenograft model. Academia Journal of Scientific Research 4:187-193, 2014
- Kang HJ, Park JH, Yoo HS, Park YM, Cho CK, Kang IC. Effects of HAD-B1 on the proliferation of A549 cisplatin-resistant lung cancer cells. Molecular Medicine Reports 17:6745-6751, 2018
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. New response evaluation criteria in solid tumours: Revised RECIST guideline(version 1.1). Eur J Cancer 45: 228-247, 2009 https://doi.org/10.1016/j.ejca.2008.10.026
- National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.5.0, 2017. Available from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0/
- Gwak MD, Suh SY. The assessment tools in palliative medicine. Korean J Hosp Palliat Care 12:177-193, 2009
- Health Insurance Review & Assessment Service. Third Assessment of Lung Cancer Appropriateness, 2017 Available from :URL: https://www.hira.or.kr/re/diag/asmWrptPopup.do?evlCd=21&pgmid=HIRAA030004000000
- Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Janne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of Crizotinib in patients with ALK-positive non-small-cell lung cancer:updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012 https://doi.org/10.1016/S1470-2045(12)70344-3
- Bang YJ. Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med 136:1201-1204, 2012 https://doi.org/10.5858/arpa.2012-0246-RA
- Yu X, Ling J, Liu X, Guo S, Lin Y, Liu X, Su L. Cordycepin induces autophagy-mediated c-FLIPL degradation and leads to apoptosis in human non-small cell lung cancer cells. Oncotarget 8(4):6691-6699, 2017
- Bizarro A, Ferreira IC, Sokovic. M, van Griensven LJ, Sousa D, Vasconcelos MH, Lima RT. Cordyceps militaris(L.) Link fruiting body reduces the growth of a non-small cell lung cancer cell line by increasing cellular levels of p53 and p21. Molecules 20(8):13927-13940, 2015 https://doi.org/10.3390/molecules200813927
- Khan MA, Ali R, Parveen R, Najmi AK, Ahmad S. Pharmacological evidences for cytotoxic and antitumor properties of Boswellic acids from Boswellia serrata. J Ethnopharmacol 191:315-323, 2016 https://doi.org/10.1016/j.jep.2016.06.053
- Choi YJ, Shin DY, Lee YW, Cho CK, Kim GY, Kim WJ, Yoo HS, Choi YH. Inhibition of cell motility and invasion by HangAmDan-B in NCI-H460 human non-small cell lung cancer cells. Oncology Reports 26(6):1601-1609, 2011 https://doi.org/10.3892/or.2011.1440
- Park SJ. Anti-lung cancer effect and toxicological evaluation of Samchilchoongcho-Jung (HAD-B1), Doctor's degree, Daejeon University, Daejeon, 2016
- Kim JH, Synergistic antitumor effects of Samchilchoongcho-Jung (HAD-B1) and afatinib on H1975 human lung cancer xenograft mouse model, Doctor's degree, Daejeon University, Daejeon, 2018